Beam Therapeutics (MEX:BEAM) Short Ratio


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
65 GF Score
Price MXN655.00
GF Value MXN509.01
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:BEAM
65GF Score
Beam Therapeutics Inc MEX:BEAM
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 28.7% above its estimated GF Value™ of MXN509.01. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Short Ratio:
  • GF Value™: MXN509.01 vs. price of MXN655.00 (28.7% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
65GF Score

Get the complete analysis for MEX:BEAM

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN509.01
GF Value